Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lead Real Estate Co., Ltd - American Depositary Shares (NQ: LRE )

1.970 -0.330 (-14.34%)
Streaming Delayed Price Updated: 3:51 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lead Real Estate Co., Ltd - American Depositary Shares

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
11 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
Via Benzinga
10 Consumer Discretionary Stocks Moving In Thursday's Intraday Session
Via Benzinga
Lead Real Estate Co. Is Helping Redefine Luxury Living In Japan And Beyond
The luxury real estate market in Japan is currently experiencing growth and increased demand. The country has seen a steady influx of wealthy individuals and foreign investors looking to invest in... 
Via Benzinga
Why Gritstone bio Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Gainers Inpixon (NASDAQ: INPX) shares rose 44.6% to $0.2023 in pre-market trading after gaining around 10% on Wednesday. 
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.